ReviewLung Cancer (Auckland, N.Z.)2017
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma.
Review in Lung Cancer (Auckland, N.Z.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Six-Gene Signature for Differential Diagnosis and Therapeutic Decisions in Non-Small-Cell Lung Cancer-A Validation Study.International journal of molecular sciences · 2024Article
- miRNA-Seq Tissue Diagnostic Signature: A Novel Model for NSCLC Subtyping.International journal of molecular sciences · 2023Article
- Current status of immunotherapy for non-small cell lung cancer.Frontiers in pharmacology · 2022Review
- Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.Frontiers in molecular biosciences · 2022Review
- PPDPF Promotes the Progression and acts as an Antiapoptotic Protein in Non-Small Cell Lung Cancer.International journal of biological sciences · 2022Article
- A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.Advances in experimental medicine and biology · 2021Review
- Efficacy of weekly amrubicin for refractory or relapsed non-small cell lung cancer: A protocol of systematic review and meta-analysis.Medicine · 2020Article
- Article
- Characterization of A Bifunctional Synthetic RNA Aptamer and A Truncated Form for Ability to Inhibit Growth of Non-Small Cell Lung Cancer.Scientific reports · 2019Article
- Article
- Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?International journal of molecular sciences · 2018Review
- In Vivo SELEX of an Inhibitory NSCLC-Specific RNA Aptamer from PEGylated RNA Library.Molecular therapy. Nucleic acids · 2018Article
- Clinicopathological significance of DAPK promoter methylation in non-small-cell lung cancer: a systematic review and meta-analysis.Cancer management and research · 2018Article
- Clinicopathological significance ofOncotarget · 2017Article
- New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Frontiers in immunology · 2017Review
- A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment options for metastatic non-small-cell lung cancer (NSCLC) have expanded dramatically in the last 10 years with the discovery of newer drugs and targeted therapy. Epidermal growth factor receptor (EGFR), when aberrantly activated, promotes cell growth and contributes in various ways to the malignant process. EGFR has become an important therapeutic target in a variety of malignancies. Small-molecule tyrosine kinase inhibitors (TKIs) of EGFR are being used to treat advanced NSCLC and are particularly effective in the presence of EGFR mutations. Monoclonal antibodies have also been developed that block the EGFR at the cell surface and work in conjunction with chemotherapy. Necitumumab is a second-generation fully human IgG1 monoclonal antibody that has shown promise in metastatic NSCLC. The benefit has mostly been restricted to squamous cell lung cancer in the frontline setting. Considering that the survival advantage for these patients was modest, there is a need to discover biomarkers that will predict which patients will likely have the best outcomes. This review focuses on the development and clinical trial experience with necitumumab in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.